Key Points
- CAO Louise Frederika Kooij sold 75,117 shares on Dec. 23 at $36.21 for $2,719,986.57, and also sold 26,011 shares on Dec. 24 and 43,872 shares on Dec. 26, cutting her ownership by 83.35% to 15,000 shares.
- NewAmsterdam Pharma (NAMS) trades around $35 with a $3.97B market cap, recent negative EPS and revenue misses, while analysts' consensus is a "Moderate Buy" with an average price target of $45.90 (8 Buys, 1 Hold, 1 Sell).
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 26,011 shares of the company's stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $35.68, for a total transaction of $928,072.48. Following the completion of the transaction, the chief accounting officer owned 15,000 shares of the company's stock, valued at $535,200. This trade represents a 63.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Louise Frederika Kooij also recently made the following trade(s):
- On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.30, for a total transaction of $1,548,681.60.
- On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $36.21, for a total transaction of $2,719,986.57.
NewAmsterdam Pharma Trading Down 0.7%
NAMS stock opened at $35.02 on Tuesday. The stock has a 50-day moving average price of $37.03 and a two-hundred day moving average price of $29.13. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $42.00. The stock has a market cap of $3.97 billion, a PE ratio of -17.08 and a beta of 0.05.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.03). The firm had revenue of $0.35 million for the quarter, compared to analyst estimates of $4.54 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%. On average, analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of analysts have recently commented on the stock. Citigroup boosted their price objective on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a "buy" rating in a research report on Friday, October 17th. HC Wainwright began coverage on shares of NewAmsterdam Pharma in a research report on Monday, October 20th. They issued a "buy" rating and a $52.00 target price for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research report on Wednesday, October 8th. Needham & Company LLC increased their price objective on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the stock a "buy" rating in a research note on Wednesday, November 5th. Finally, Royal Bank Of Canada lifted their target price on NewAmsterdam Pharma from $39.00 to $44.00 and gave the company an "outperform" rating in a research report on Thursday, November 6th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $45.90.
Get Our Latest Stock Report on NAMS
Institutional Investors Weigh In On NewAmsterdam Pharma
A number of institutional investors and hedge funds have recently modified their holdings of the company. Quarry LP bought a new position in NewAmsterdam Pharma during the first quarter worth about $25,000. Mather Group LLC. acquired a new stake in shares of NewAmsterdam Pharma in the third quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of NewAmsterdam Pharma during the 3rd quarter worth approximately $30,000. Wolverine Asset Management LLC bought a new stake in NewAmsterdam Pharma in the 3rd quarter valued at $69,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of NewAmsterdam Pharma by 18.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company's stock valued at $79,000 after purchasing an additional 662 shares during the last quarter. 89.89% of the stock is owned by institutional investors.
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
